INTS
Intensity Therapeutics, Inc. Common stock
NASDAQ: INTS · HEALTHCARE · BIOTECHNOLOGY
$5.21
+0.06% today
Updated 2026-05-06
Market cap
$13.80M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-8.56
Dividend yield
—
52W range
$5 – $44
Volume
0.0M
Intensity Therapeutics, Inc. Common stock (INTS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | $179037.00 | $147000.00 | $25000.00 | $26000.00 |
| Gross profit | — | — | — | $-179037.00 | $-147000.00 | $-25000.00 | $-26000.00 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $4.44M | $5.05M | $5.86M | $5.13M | $4.79M | $10.50M | $6.79M |
| SG&A | $1.24M | $1.17M | $2.16M | $2.42M | $3.53M | $6.09M | $5.19M |
| Operating income | $-5.68M | $-6.22M | $-8.01M | $-7.55M | $-8.32M | $-16.59M | $-11.97M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-5.68M | $-6.22M | $-8.01M | $-7.50M | $-10.09M | $-16.27M | $-11.97M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-5.68M | $-6.22M | $-8.01M | $-7.58M | $-10.23M | $-16.27M | — |
| Interest expense | — | — | $16767.00 | $81781.00 | $305000.00 | $0.00 | — |
| Income tax | $-150707.00 | $-74009.00 | $-2609.00 | $-131908.00 | $1.00 | — | — |
| Effective tax rate | 2.8% | 1.2% | 0.0% | 1.7% | -0.0% | 0.0% | 0.0% |
| Net income | $-5.23M | $-5.96M | $-7.89M | $-7.58M | $-10.54M | $-16.27M | $-11.61M |
| Net income growth (YoY) | — | -13.9% | -32.5% | +3.9% | -39.0% | -54.4% | +28.7% |
| Profit margin | — | — | — | — | — | — | — |